From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

Preclinical application of a CD155 targeting chimeric antigen receptor T cell therapy for digestive system cancers

Last Updated: Tuesday, April 22, 2025

Researchers developed a CD155-based CAR for the treatment of digestive system cancers. They found that these CAR T cells showed significant antitumor activity in vivo, suggesting that CD155 is a promising target for digestive system cancer therapy. 

Oncogene
Advertisement
News & Literature Highlights
Advertisement
Advertisement